Bora Pharmaceuticals signs manufacturing deal with Onconic to support U.S. JAQBO trial supply

• Bora Pharmaceuticals signed a manufacturing agreement with Onconic Therapeutics to support U.S. clinical development of JAQBO GERD tablets.
• Bora’s Maple Grove, Minnesota oral solid dose facility will manufacture, package, run QC and stability testing, prepare CMC documentation for a planned U.S. Phase 3.
• JAQBO, a potassium-competitive acid blocker, won South Korea approval in April 2024; launch in October 2024; Onconic is expanding global partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bora Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607230815BIZWIRE_USPR_____20260723_BW479111) on July 23, 2026, and is solely responsible for the information contained therein.